Report Code: A02400 | Pages: NA | ||
Tables: NA | Charts: NA |
|
Ionizing radiations are used to treat cancer and the procedure is known as radiation therapy. When the ionizing radiations are made up of charged particles such as protons, carbon, and other ions, then radiation therapy is called as hadron therapy.
These charged particles have unique physical and radiobiological properties such as less diffusion that allows them to penetrate the tissues and destroy the cancerous cells with maximum energy. Hadron therapy destroys the cancerous cells by damaging their DNA. This therapy is more advantageous than the traditional approach as it delivers long-term protection against cancer, has minimal side effects, and avails treatment to more cancer types.
There are many factors, such as increase in incidence of cancer, rise in healthcare expenditure, increased access to medical insurance, and technological advancements in cancer treatment therapies that fuel the growth of the global hadron therapy market.
However, the factors such as lack of awareness about hadron therapy, and less number of therapy providers are anticipated to inhibit the growth of the market. Also, the high product developmental cost is expected to impede the growth of the market.
The market is segmented based on type, application, end-users, and geography. By type, the market is categorized into electron beam, proton beam, neutron beam, carbon ion beam, alpha particle beam, and beta particle beam. By application, it is classified into pediatric cancer, bone and soft tissue cancer, prostate cancer, lung cancer, liver cancer, eye cancer, head & neck cancer, and other applications. By end users, it is divided into hospitals, cancer research centers, and clinics. By geography, it is studied across North America, Europe, Asia Pacific, and LAMEA.
Key Benefits
Hadron Therapy Market Report Highlights
Aspects | Details |
---|---|
By Type |
|
By Application |
|
By End Users |
|
By Region |
|
Key Market Players | Koninklijke Philips N.V., Hitachi, Ltd., Sumitomo Corporation, Optivus Proton Therapy, Inc., Mevion Medical Systems, Varian Medical Systems, Inc., Mitsubishi Electric Corporation, ProTom International, Advanced Oncotherapy, ProNova Solutions, LLC. |
List of other players (These companies are not profiled in the report and same can be done on demand) | Seattle Genetics, Peregrine Pharmaceuticals, Viralytics Ltd., Takeda Pharmaceutical Company Ltd., Amgen Inc., IBA Worldwide, F. Hoffmann-La Roche AG |
Loading Table Of Content...
Start reading.
This Report and over 71,339+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of the scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time for readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of the scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save the time of readers